Exosomes in Plasma of Patients with Ovarian Carcinoma: Potential Biomarkers of Tumor Progression and Response to Therapy
|Marta Szajnik1,5, Magdalena Derbis2, Michal Lach2, Paulina Patalas2, Marcin Michalak1, Hanna Drzewiecka3, Dariusz Szpurek4, Andrzej Nowakowski5, Marek Spaczynski1, WÅodzimierz Baranowski5 and Theresa L. Whiteside6*|
|1Department of Gynecology Oncology, Poznan University of Medical Sciences, 61-701 Poznan, Poland|
|2Department of Clinical Immunology, Poznan University of Medical Sciences, 61-701 Poznan, Poland|
|3Department of Biochemistry and Molecular Biology,Poznan University of Medical Sciences, 61-701 Poznan, Poland|
|4Division of Gynecology Surgery, Poznan University of Medical Sciences, 61-701 Poznan, Poland|
|5Department of Gynecology and Gynecologic Oncology, Military Institute of Medicine, Warsaw, Poland|
|6University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213, USA|
|Corresponding Author :||Theresa L Whiteside
University of Pittsburgh Cancer Institute
5117 Centre Ave., Suite 1.27, Pittsburgh, PA 15232, USA
E-mail: [email protected]
|Received March 20, 2013; Accepted April 25, 2013; Published April 29, 2013|
|Citation: Szajnik M, Derbis M, Lach M, Patalas P, Michalak M, et al. (2013) Exosomes in Plasma of Patients with Ovarian Carcinoma: Potential Biomarkers of Tumor Progression and Response to Therapy. Gynecol Obstetric S4:003. doi:10.4172/2161-0932.S4-003|
|Copyright: © 2013 Szajnik M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at
Pubmed Scholar Google
Background: In patients with Ovarian Cancer (OvCa) exosomes released by tumor cells are present in the plasma and could be involved in tumor progression. This study examines the association between the exosome presence/protein content in plasma of OvCa patients and disease outcome, response to standard therapy and/or tumorresistance to therapies in patients studied at diagnosis and also serially during and after therapy.
Design and methods: Exosomes were purified from OvCa patients’ plasma (n=22), patients with benign tumors (n=10) or (n=10) healthy controls (NC) using ultracentrifugation. Exosomes were visualized by scanning electron microscopy. Their protein content was measured. The presence of MAGE 3/6 and TGF-β1 in exosomes was evaluated in Western blots.
Results: The OvCa patients’ plasma contained higher levels of exosomal proteins (p<0.05) compared to those isolated from plasma of patients with benign tumors or NC. Exosomes isolated from OvCa patients’s plasma carried TGF-β1 and MAGE3/6, which distinguished OvCa patients from those with benign tumors and NC. High protein levels of exosomes were seen in newly diagnosed patients; however in advanced stages of OvCa patients the protein content of isolated exosomes was significantly higher than that of early stages. The exosome levels variably changed during/ after chemotherapy, and correlations between the changes in exosomal protein levels and clinical data suggested that the protein content of exosomes might be useful in predicting responses to therapy and prognosis in OvCa patients.
Conclusion: Analysis of plasma exosomes levels offers a novel approach to diagnosis and monitoring response to therapies in OvCa patients.